Search results
Results From The WOW.Com Content Network
However, I think it's a good choice for income investors, with its forward dividend yield of nearly 4% and an improving outlook. Should you invest $1,000 in Viatris right now? Before you buy stock ...
Viatris stock trades at a forward price-to-earnings (P/E) ratio of just 4.33, well below the industry average of 17. ... Viatris offers shareholders a hefty 4.12% dividend yield. The downside is ...
Viatris expects full-year earnings in the range of $2.56 to $2.71 per share, with revenue in the range of $14.6 billion to $15.1 billion. ... Access a Zacks stock report on VTRS at https://www ...
Viatris (VTRS) Q3 results are likely to be impacted by foreign exchange rate fluctuations. An update on the deal with Biocon is also expected along with the results.
In 1976 the stock moved to the National Association of Securities Dealers Automated Quotations . Their final stock move was in 1986, when their stock became available for trade on the New York Stock Exchange under the ticker symbol MYL. Prior to the Viatris combination, the stock was traded on the NASDAQ.
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn , a legacy division of Pfizer , on November 16, 2020.
When it made its debut last November, Viatris (VTRS) was touted as a value-unlocking divestiture. The pharmaceutical company, formed when Pfizer (PFE) merged its Upjohn unit with Mylan NV, started ...
Viatris (VTRS) beats on Q3 earnings and sales. The company raises the lower end of its annual revenue guidance. Skip to main content. 24/7 Help. For premium support please call: 800-290-4726 ...